WO2015163316A1 - 末梢神経障害の予防又は改善用組成物 - Google Patents
末梢神経障害の予防又は改善用組成物 Download PDFInfo
- Publication number
- WO2015163316A1 WO2015163316A1 PCT/JP2015/062092 JP2015062092W WO2015163316A1 WO 2015163316 A1 WO2015163316 A1 WO 2015163316A1 JP 2015062092 W JP2015062092 W JP 2015062092W WO 2015163316 A1 WO2015163316 A1 WO 2015163316A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peripheral neuropathy
- serine
- composition
- group
- pain
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 139
- 208000033808 peripheral neuropathy Diseases 0.000 title claims abstract description 99
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract description 86
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims abstract description 60
- 150000001413 amino acids Chemical class 0.000 claims abstract description 43
- 230000000694 effects Effects 0.000 claims abstract description 39
- 150000002632 lipids Chemical class 0.000 claims abstract description 27
- 239000004473 Threonine Substances 0.000 claims description 61
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 47
- 239000002246 antineoplastic agent Substances 0.000 claims description 38
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 32
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 32
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 32
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 28
- 208000003947 Knee Osteoarthritis Diseases 0.000 claims description 14
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 14
- 229940041181 antineoplastic drug Drugs 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- 238000004806 packaging method and process Methods 0.000 claims description 14
- 210000000578 peripheral nerve Anatomy 0.000 claims description 13
- 230000037406 food intake Effects 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 8
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 7
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 7
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 7
- 238000007906 compression Methods 0.000 claims description 7
- 230000006835 compression Effects 0.000 claims description 7
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 7
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 7
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 claims description 6
- 235000021294 Docosapentaenoic acid Nutrition 0.000 claims description 6
- 208000017169 kidney disease Diseases 0.000 claims description 5
- 201000008482 osteoarthritis Diseases 0.000 claims description 5
- 210000001032 spinal nerve Anatomy 0.000 claims description 5
- 208000028389 Nerve injury Diseases 0.000 claims description 3
- 230000008764 nerve damage Effects 0.000 claims description 3
- 208000037157 Azotemia Diseases 0.000 claims 1
- 208000009852 uremia Diseases 0.000 claims 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 abstract description 139
- -1 serine Chemical class 0.000 abstract description 17
- 229960001153 serine Drugs 0.000 description 108
- 208000002193 Pain Diseases 0.000 description 92
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 73
- 229960002898 threonine Drugs 0.000 description 59
- 230000037396 body weight Effects 0.000 description 54
- 238000012360 testing method Methods 0.000 description 48
- 230000004044 response Effects 0.000 description 40
- 206010003246 arthritis Diseases 0.000 description 39
- 229940024606 amino acid Drugs 0.000 description 36
- 235000001014 amino acid Nutrition 0.000 description 36
- 239000000411 inducer Substances 0.000 description 31
- 206010020751 Hypersensitivity Diseases 0.000 description 27
- 241000700159 Rattus Species 0.000 description 19
- 150000003839 salts Chemical class 0.000 description 17
- 238000011156 evaluation Methods 0.000 description 16
- 208000026935 allergic disease Diseases 0.000 description 15
- 230000009610 hypersensitivity Effects 0.000 description 15
- 210000003127 knee Anatomy 0.000 description 15
- 235000012054 meals Nutrition 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 230000000638 stimulation Effects 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 11
- 235000013305 food Nutrition 0.000 description 10
- 210000002414 leg Anatomy 0.000 description 10
- 230000001603 reducing effect Effects 0.000 description 9
- 206010021033 Hypomenorrhoea Diseases 0.000 description 8
- 210000000845 cartilage Anatomy 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 210000003205 muscle Anatomy 0.000 description 8
- 238000007427 paired t-test Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 210000003414 extremity Anatomy 0.000 description 7
- 239000003925 fat Substances 0.000 description 7
- 235000019197 fats Nutrition 0.000 description 7
- 235000021323 fish oil Nutrition 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 208000004296 neuralgia Diseases 0.000 description 6
- 208000021722 neuropathic pain Diseases 0.000 description 6
- 230000002093 peripheral effect Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 229920000392 Zymosan Polymers 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940093656 eicosapentaenoic acid 100 mg Drugs 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 4
- 239000005018 casein Substances 0.000 description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 4
- 235000021240 caseins Nutrition 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229940025174 eicosapentaenoic acid 300 mg Drugs 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 210000001044 sensory neuron Anatomy 0.000 description 4
- 208000000094 Chronic Pain Diseases 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 3
- 208000031481 Pathologic Constriction Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 210000000629 knee joint Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000005499 meniscus Effects 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 210000003594 spinal ganglia Anatomy 0.000 description 3
- 208000005801 spondylosis Diseases 0.000 description 3
- 230000036262 stenosis Effects 0.000 description 3
- 208000037804 stenosis Diseases 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010066871 Disuse syndrome Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 239000010775 animal oil Substances 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004705 lumbosacral region Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 230000003040 nociceptive effect Effects 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
- 208000027232 peripheral nervous system disease Diseases 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 210000000697 sensory organ Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229940083542 sodium Drugs 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 230000009159 somatosensory pathway Effects 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WLDHEUZGFKACJH-ZRUFZDNISA-K Amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1\N=N\C1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-ZRUFZDNISA-K 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000270722 Crocodylidae Species 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 206010050296 Intervertebral disc protrusion Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 206010060820 Joint injury Diseases 0.000 description 1
- 208000016593 Knee injury Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 108010070551 Meat Proteins Proteins 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 206010029174 Nerve compression Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010040021 Sensory abnormalities Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000004283 Sodium sorbate Substances 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 206010041549 Spinal cord compression Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002814 antineoplastic antimetabolite Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- LNNWVNGFPYWNQE-GMIGKAJZSA-N desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000020931 dietary conditions Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- AOHJOMMDDJHIJH-UHFFFAOYSA-N propylenediamine Chemical compound CC(N)CN AOHJOMMDDJHIJH-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 210000000449 purkinje cell Anatomy 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 150000003355 serines Chemical class 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 description 1
- 235000019250 sodium sorbate Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000012453 solvate Chemical class 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a composition for preventing or improving peripheral neuropathy, which contains serine and n-3 fatty acids as active ingredients.
- Neuroneuropathic pain is more likely to become chronic and has characteristics that are different from “nociceptive” pain, which is often acute (eg, injuries, burns, etc.). Acute pain following body tissue damage serves as an alarm for body tissue damage and leads the body tissue to repair over a period of time. On the other hand, it is said that chronic pain does not work as a protective biological function and continues for several months to several years (Non-patent Document 1).
- Non-Patent Document 2 Psychiamic Pain and depression associated with pain have a significant effect on the amount of activity, so removing pain can improve quality of life.
- Pain due to peripheral neuropathy is pain caused by primary damage or abnormal function in any part of the peripheral nerve transmission system.
- the cause of this nerve injury is mainly trauma or injury to the peripheral nerve, plexus or perineural soft tissue. Pain due to peripheral neuropathy also occurs with injury to central somatosensory pathways (eg, ascending somatosensory pathways in the spinal cord, brainstem, thalamus or cortex). Pain caused by peripheral neuropathy is induced by any of neurodegenerative diseases, bone degenerative diseases, metabolic disorders, cancer, infection, inflammation, surgical operation, trauma, radiation therapy, treatment with anticancer drugs, etc. Is done.
- the function of the knee joint is reduced due to muscular weakness, aging, obesity, etc. of the elderly, and the meshing of the knee cartilage and meniscus is loosened, causing deformation and tearing.
- Such loosening, deformation, and tearing of the knee cartilage and meniscus meshing occurs when the knee cartilage and meniscus acting as a cushion for the knee joint are worn and deformed little by little over a long period of activity, It may occur due to illness or injury such as rheumatoid arthritis or knee injury. In many of these, there is an excessive retention of joint fluid due to inflammation and is painful.
- deterioration of function due to muscle weakness, aging, obesity, etc. in the elderly can occur in the waist with cartilage as well as the knee, causing loosening, deformation or tearing of the lumbar engagement, chronic pain Is often accompanied.
- Non-patent Document 3 In cancer patients, unbearable numbness, aching sensation, etc. persist for a long time due to peripheral nerve and spinal cord compression caused by cancer, tissue infiltration, or peripheral nerve damage due to the action of chemotherapy itself. In particular, the pain due to chemotherapy is often forced to stop chemotherapy, and the pain due to chemotherapy is a major obstacle to cancer treatment (Non-patent Document 3).
- Peripheral neuropathy is characterized by a hypersensitive response (allodynia) in which pain is felt by stimuli that healthy individuals do not feel. Although the molecular mechanism of this onset has not been fully clarified, abnormal responses such as excessive excitement and sustained spontaneous excitement occur in sensory neurons in common with various peripheral neuropathies.
- Non-Patent Document 1 For peripheral neuropathic pain, opioid central analgesics such as morphine; steroids; non-steroidal anti-inflammatory analgesics; (Non-Patent Document 1). Therefore, there is a need for a method that can reduce peripheral neuropathic pain effectively with few side effects.
- opioid central analgesics such as morphine; steroids; non-steroidal anti-inflammatory analgesics; (Non-Patent Document 1). Therefore, there is a need for a method that can reduce peripheral neuropathic pain effectively with few side effects.
- Serine is a kind of non-essential amino acid and is involved in the biosynthesis of nucleic acids such as purines and pyrimidines and the biosynthesis of cysteine.
- nucleic acids such as purines and pyrimidines
- cysteine has been reported to be involved in the promotion of dorsal root ganglion neurite outgrowth in chicken embryo cells, the survival and development of rat fetal cell-derived hippocampal neurons and rat cerebellar Purkinje neurons ( Non-patent documents 4, 5, 6).
- All of these reports are in-vitro assessments in the early stages of neuronal development, which is very different from the situation in which peripheral neuropathy occurred after neuronal cells were formed.
- Patent Document 1 it has been reported that L-serine exhibits a reducing effect on peripheral neuropathic pain in an anticancer drug or a model animal of diabetes. Anticancer drugs and diabetes directly affect peripheral nerve cells and nerve axons.
- peripheral neuropathic pain due to knee arthritis is pain that acts locally on the sensory organs of the knee, and the nature of the pain is different from that caused by anticancer drugs or diabetes.
- the peripheral neuropathic pain caused by this knee arthritis has not been studied in Patent Document 1.
- the alleviation effect of L-serine on the pain of peripheral neuropathy caused by anticancer drugs and diabetes which was examined in Patent Document 1, was partial even at the maximum concentration of L-serine.
- eicosapentaenoic acid has already been used clinically as an agent for improving hypertriglyceridemia, but clinical reports regarding pain relief are not clear. Even in studies using animal models, there is no report that clearly shows a mitigating effect on mechanical stimulation of peripheral nerves when eicosapentaenoic acid is added to a meal and ingested.
- the problem to be solved by the present invention is to provide a novel composition having an effect of preventing or improving peripheral neuropathy.
- peripheral neuropathy can be prevented or ameliorated by adding serine and n-3 fatty acids, and the present invention has been completed. .
- the present invention is as follows.
- a composition for preventing or ameliorating peripheral neuropathy comprising a serine-containing amino acid and an n-3 fatty acid-containing lipid.
- the n-3 fatty acid contains one or more selected from the group consisting of eicosapentaenoic acid, docosapentaenoic acid and docosahexaenoic acid.
- the amount of serine is 50% by weight or more based on the total amount of amino acids.
- Peripheral neuropathy is a peripheral neuropathy caused by an anticancer agent, a peripheral neuropathy caused by knee osteoarthritis, a spinal nerve disorder, a peripheral neuropathy caused by mechanical compression of a peripheral nerve trunk, a diabetic peripheral neuropathy,
- a composition for preventing or ameliorating a decrease in activity due to peripheral neuropathy comprising a serine-containing amino acid and an n-3 fatty acid-containing lipid.
- a method for preventing or ameliorating peripheral neuropathy comprising administering an effective amount of a composition containing an amino acid containing serine and a lipid containing an n-3 fatty acid to a subject in need thereof.
- the n-3 fatty acid contains one or more selected from the group consisting of eicosapentaenoic acid, docosapentaenoic acid and docosahexaenoic acid.
- the amount of serine in the composition is 50% by weight or more based on the total amount of amino acids in the composition.
- the composition is in a unit package form per ingestion, contains 0.1 g or more of serine per unit, and contains 0.03 g or more of n-3 fatty acid per unit. [11 ] To [15].
- Peripheral neuropathy is a peripheral neuropathy caused by an anticancer agent, a peripheral neuropathy caused by knee osteoarthritis, a spinal nerve disorder, a peripheral neuropathy caused by mechanical compression of a peripheral nerve trunk, a diabetic peripheral neuropathy, The method according to any one of [11] to [16], wherein the method is any one selected from the group consisting of renal disease urine toxicity peripheral neuropathy, shingles peripheral neuropathy, and Guillain-Barre syndrome. [18] The method according to any one of [11] to [16], wherein the peripheral neuropathy is a peripheral neuropathy caused by an anticancer agent or a peripheral neuropathy caused by osteoarthritis of the knee. [19] Prevention or improvement of decreased activity due to peripheral neuropathy, comprising administering an effective amount of a composition containing an amino acid containing serine and a lipid containing n-3 fatty acid to a subject in need thereof Method.
- a composition comprising a serine-containing amino acid and an n-3 fatty acid-containing lipid for use in the prevention or amelioration of peripheral neuropathy.
- the n-3 fatty acid contains one or more selected from the group consisting of eicosapentaenoic acid, docosapentaenoic acid and docosahexaenoic acid.
- the amount of serine is 50% by weight or more based on the total amount of amino acids.
- Peripheral neuropathy is a peripheral neuropathy caused by an anticancer agent, a peripheral neuropathy caused by osteoarthritis of the knee, a spinal nerve disorder, a peripheral neuropathy caused by mechanical compression of a peripheral nerve trunk, a diabetic peripheral neuropathy,
- composition containing an amino acid containing serine and a lipid containing n-3 fatty acids for use in preventing or ameliorating a decrease in activity due to peripheral neuropathy [29] The composition according to any one of [20] to [28], which is a pharmaceutical.
- a composition for preventing or improving peripheral neuropathy can be provided.
- the composition has an effect of reducing pain of peripheral neuropathy, peripheral neuropathy caused by administration of an anticancer agent, peripheral neuropathy caused by osteoarthritis of the knee, spinal neuropathy (eg, disc herniation, lumbar region) Spinal canal stenosis, deformed spondylosis, etc., peripheral neuropathy due to mechanical compression of peripheral nerve trunk, diabetic peripheral neuropathy, renal urine peripheral neuropathy, peripheral neuropathy due to shingles, Guillain-Barre syndrome, etc.
- the said composition can prevent or improve the active mass fall by peripheral neuropathy.
- the composition contains serine and n-3 fatty acid, which have established safety, as active ingredients, it can be safely ingested over a long period of time, and the QOL of the ingestor can be increased.
- the vertical axis (Overall response (%)) indicates the ratio (%) of the frequency of pain response to the number of times the filament is pressed. It is the result of the Von Frey test with respect to the left foot 7 days after administration of the knee arthritis inducer in Test Example 2. * Indicates that there is a significant difference (p ⁇ 0.05, non-paired t-test) compared to the 2B group.
- the vertical axis (Overall response (%)) indicates the ratio (%) of the frequency of pain response to the number of times the filament is pressed. It is the result of the Von Frey test with respect to the right leg 14 days after administration of the knee arthritis inducer in Test Example 2.
- the vertical axis (Gastrocnemus muscle (g)) indicates the weight (g) of the scissors muscle. 4 is a ratio (right foot / left foot) between the weight of the right leg and the left leg in Test Example 2. * Indicates that there is a significant difference (p ⁇ 0.05, non-paired t-test) compared to the 2B group.
- the vertical axis (Gastrocnemus muscle ratio.) Shows the ratio (right foot / left foot) between the weight of the right foot and the left foot. It is the result of the Von Frey test with respect to the right leg 21 days after administration of the knee arthritis inducer in Test Example 3.
- FIG. 9 is a measurement result of behavior amounts of groups 5A to 5C in Test Example 5.
- FIG. The vertical axis (AUC (10 3 Counts ⁇ min)) represents the cumulative number of times that the rat has passed the infrared sensor in the cage.
- the composition for preventing or ameliorating peripheral neuropathy of the present invention mainly comprises an amino acid containing serine and a lipid containing n-3 fatty acids.
- prevention of peripheral neuropathy refers to preventing the manifestation of symptoms in individuals who do not exhibit various symptoms of peripheral neuropathy (eg, hypersensitive pain, sensory abnormalities, etc.). Prevention).
- improvement of peripheral neuropathy means to reduce the symptoms or prevent or delay the deterioration of the symptoms in an individual exhibiting various symptoms of peripheral neuropathy.
- the amino acid used in the present invention contains serine as an essential component.
- the form of the serine is not particularly limited, and may be any form of a free form, a peptide constituent amino acid, and a protein constituent amino acid. When free serine is used, it may be in the form of a salt or a solvate thereof, or a mixture thereof.
- Examples of serine salts include acid addition salts and salts with bases, and physiologically acceptable salts are preferred.
- acids that form physiologically acceptable salts of serine include inorganic acids such as hydrogen chloride, hydrogen bromide, sulfuric acid, and phosphoric acid; acetic acid, lactic acid, citric acid, tartaric acid, maleic acid, fumaric acid, monomethyl Organic acids such as sulfuric acid can be mentioned.
- bases that form physiologically acceptable salts of serine include, for example, metal (eg, sodium, potassium, calcium, etc.) hydroxides or carbonates, inorganic bases such as ammonia; ethylenediamine, propylenediamine, ethanolamine. And organic bases such as monoalkylethanolamine, dialkylethanolamine, diethanolamine, and triethanolamine. These salts may be either a single salt or a combination of two or more salts.
- the free serine used in the present invention may be any of the L-form, D-form and DL-form, but the L-form is preferred.
- the production method of serine is not particularly limited, and can be produced by a method known per se (eg, protein hydrolysis method, chemical synthesis method, enzyme method, fermentation method, etc.). Moreover, you may use a commercial item. Serine can also be obtained by enzymatic hydrolysis of an animal or plant-derived natural protein having an amino acid sequence containing the serine residue.
- the composition of the present invention may contain amino acids other than serine (eg, threonine, glycine, etc.) in addition to serine.
- the form of these amino acids is not particularly limited, and may be a free form and a salt thereof, or a peptide form in which two or more amino acids are peptide-bonded.
- the protein may be in the form of a protein, for example, animal protein (eg, casein, acid casein, casein sodium, casein calcium, whey protein, whey whey protein, fish meat protein, egg protein, and And hydrolysates thereof) and vegetable proteins (eg, soy protein, wheat protein, corn protein, and hydrolysates thereof).
- the amino acid used in the composition of the present invention may be any of L-form, D-form and DL-form.
- the amount of serine in the composition of the present invention is preferably 50% by weight or more, more preferably 70% by weight or more, and particularly preferably 90% by weight or more based on the total amount of amino acids.
- the amount of serine in the composition of the present invention is calculated as the sum of the weights of all forms of serine contained in the composition of the present invention.
- the form of serine is other than the free form, for example, a salt or a constituent amino acid of a peptide and protein
- the “total amount of amino acids” is calculated as the total weight of all forms of amino acids (eg, free amino acids and salts thereof, peptides, proteins, etc.) contained in the composition of the present invention.
- the weight of the amino acid is converted to the weight of the free form.
- the upper limit of the amount of serine in the composition of the present invention is not particularly limited, but is usually 100% by weight, preferably 95% by weight, based on the total amount of amino acids.
- the weight ratio of serine to threonine is preferably a specific value or more.
- the weight ratio of serine to threonine is equal to or higher than a specific value, the composition of the present invention sufficiently exhibits a desired effect (eg, an effect of reducing pain of peripheral neuropathy, etc.). Can do.
- the weight ratio of serine to threonine (serine / threonine) is preferably 2.60 or more, more preferably 5.20 or more, and particularly preferably 10.40 or more.
- the weight ratio of serine to threonine is a value obtained by dividing the amount of serine in the composition of the present invention by the amount of threonine in the present invention.
- the amount of threonine in the composition of the present invention is calculated as the sum of the weights of all forms of threonine contained in the composition of the present invention.
- the form of threonine is other than the free form, for example, a salt, or a constituent amino acid of peptides and proteins, the weight of the threonine is converted to the weight of the free form.
- Table 1 shows the weight ratio (serine / threonine) of serine and threonine contained in 100 g of food edible portion of natural food materials (“Japanese Food Standard Component Conformity Amino Acid Composition Table 2010” (Ministry of Education, Culture, Sports, Science and Technology) Calculated based on the Council's Resource Research Subcommittee).
- a natural food material cannot achieve a food having a weight ratio of serine to threonine (serine / threonine) of 2.60 or more. In order to obtain such a food, it is necessary to add, for example, free serine to a natural food material.
- the upper limit of the weight ratio of serine to threonine is not particularly limited, and the smaller the amount of threonine, the more preferable.
- the composition of the present invention most preferably does not substantially contain threonine.
- the weight ratio of threonine to serine is preferably 0.38 or less, more preferably 0. .20 or less, particularly preferably 0.10 or less, and most preferably 0.
- substantially free of threonine means (a) no threonine or (b) an amount that does not affect the effect of the composition of the present invention (for example, relative to the total amount of amino acids). 1% by weight or less, preferably 0.1% by weight or less).
- threonine taken from a meal or the like may affect the effect of the composition of the present invention.
- Ingestion eg, meal
- the total amount of amino acids contained in the composition of the present invention is usually 1 to 90% by weight, preferably 5 to 85% by weight, based on the whole composition.
- the lipid used in the composition of the present invention contains n-3 fatty acid as an essential component.
- n-3 fatty acid in the present specification means an unsaturated fatty acid having a double bond third from the methyl group at the end of the hydrocarbon chain, specifically, eicosapentaenoic acid, docosahexaenoic acid, Examples include ⁇ -linolenic acid and docosapentaenoic acid.
- n-3 fatty acid used in the composition of the present invention is preferably eicosapentaenoic acid, docosahexaenoic acid and docosapentaenoic acid, particularly preferably eicosapentaenoic acid.
- n-3 fatty acids may be used alone or in combination of two or more.
- eicosapentaenoic acid may be abbreviated as “EPA”.
- N-3 fatty acids are abundantly contained in oils and fats such as fish oil, perilla oil and linseed oil, and those extracted and purified from these oils and fats can be used.
- oils and fats such as fish oil, perilla oil and linseed oil, and those extracted and purified from these oils and fats can be used.
- those produced by a method known per se eg, chemical synthesis method, fermentation method, etc.
- Commercial products marketed for food can also be used.
- fats and oils rich in n-3 fatty acids can be used as they are.
- the lipid contained in the composition of the present invention may contain other lipids in addition to n-3 fatty acids.
- the lipid include edible vegetable oils such as cottonseed oil, sunflower oil, peanut oil, rapeseed oil, soybean oil, safflower oil, olive oil, rice bran oil, corn oil, sesame oil, cocoa butter; beef fat, pork fat, fish oil, butter, Edible animal oils such as butter oil; processed fats and oils such as shortening; medium chain fatty acid oils such as coconut oil, palm oil, and palm kernel oil.
- edible vegetable oils such as cottonseed oil, sunflower oil, peanut oil, rapeseed oil, soybean oil, safflower oil, olive oil, rice bran oil, corn oil, sesame oil, cocoa butter
- beef fat, pork fat, fish oil, butter, Edible animal oils such as butter oil
- processed fats and oils such as shortening
- medium chain fatty acid oils such as coconut oil, palm oil, and palm kernel oil.
- the amount of n-3 fatty acid is preferably 20% by weight or more, more preferably 25% by weight or more, particularly preferably 30% by weight or more, based on the total amount of lipids contained in the composition of the present invention. It is.
- the upper limit of the amount of n-3 fatty acid is not particularly limited.
- the content of eicosapentaenoic acid with respect to the total amount of the n-3 fatty acid is usually 5 to 100% by weight, from the viewpoint of suppressing oil intake even a little,
- the amount is preferably 10 to 100% by weight, more preferably 50 to 100% by weight.
- the total amount of lipid contained in the composition of the present invention is usually 1 to 90% by weight, preferably 5 to 85% by weight, based on the whole composition.
- composition of the present invention can be provided as a medicine or the like.
- administration subjects include mammals (eg, humans, mice, rats, hamsters, rabbits, cats, dogs, cows, sheep, monkeys, etc.), and preferably humans.
- the dosage form is not particularly limited, and may be either an oral medicine or a parenteral medicine.
- oral medicines include tablets, granules, powders, capsules (including soft capsules), elixirs, syrups, microcapsules, drinks, emulsions, suspensions, etc.
- oral medicines include tablets, granules, powders, capsules (including soft capsules), elixirs, syrups, microcapsules, drinks, emulsions, suspensions, etc.
- Examples include external preparations for skin (eg, ointments, creams, gels, solutions, lotions, packs, bathing agents, etc.), injections, and the like. It can also be used in combination with currently marketed analgesics (opioid central analgesics; steroids; nonsteroidal anti-inflammatory analgesics, etc.).
- Serine and n-3 fatty acids which are active ingredients of the composition of the present invention, can be contained in a plurality (two or more) of the compositions alone or in combination.
- the plurality of compositions may be, for example, a combination of two or more medicaments.
- the amount of serine relative to the total amount of amino acids, the amount of n-3 fatty acids relative to the total amount of lipids, and the amount of eicosapentaenoic acid relative to the total amount of n-3 fatty acids Content etc. are computed from the total amount of each component contained in a some composition.
- composition of the present invention may contain a carrier conventionally used in the field of medicine or the like, if necessary, as long as the object of the present invention is not impaired.
- composition of the present invention is an oral medicine or the like
- carriers include binders such as tragacanth, gum arabic, corn starch, gelatin, and high molecular weight polyvinylpyrrolidone; cellulose and its derivatives (eg, fine Excipients such as crystalline cellulose, crystalline cellulose, hydroxypropyl cellulose, etc .; swelling agents such as corn starch, pregelatinized starch, alginic acid, dextrin; lubricants such as magnesium stearate; fluidity such as fine silicon dioxide, methylcellulose, etc.
- binders such as tragacanth, gum arabic, corn starch, gelatin, and high molecular weight polyvinylpyrrolidone
- cellulose and its derivatives eg, fine Excipients such as crystalline cellulose, crystalline cellulose, hydroxypropyl cellulose, etc .
- swelling agents such as corn starch, pregelatinized starch, alginic acid, dextrin
- Lubricants such as glycerin fatty acid ester, talc, polyethylene glycol 6000; thickeners such as sodium carboxymethylcellulose, carboxyvinyl polymer, xanthan gum, gelatin; sweeteners such as sucrose, lactose, aspartame; peppermint tofu -Flavoring agents such as flavors, crocodile flavors, cherry flavors and orange flavors; emulsifiers such as monoglycerides, polyglycerin fatty acid esters, sucrose fatty acid esters, lecithin, polyoxyethylene hydrogenated castor oil, polyoxyethylene monostearate; citric acid PH adjusters such as sodium citrate, acetic acid, sodium acetate and sodium hydroxide; thickeners such as sodium carboxymethylcellulose, carboxyvinyl polymer, xanthan gum and gelatin; flavoring agents such as aspartame, licorice extract and saccharin; , Antioxidants such as butylhydroxyanisole and propyl
- examples of the carrier that may be contained include higher fatty acid esters such as petrolatum, liquid paraffin, isopropyl myristate, octyldodecyl myristate; squalane, lanolin, cetanol and the like Higher alcohols; oily bases such as silicone oils and animal and vegetable oils; lower alcohols such as ethanol; polyhydric alcohols such as polyethylene glycol and propylene glycol; ⁇ -monoglyceryl ether, lecithin, sorbitan fatty acid ester, dextrin fatty acid Emulsifiers or emulsion stabilizers such as esters, fatty acid monoglycerides, fatty acid metal salts, magnesium sulfate; fragrances; antiseptics; pigments; thickeners; antioxidants; UV protection agents; Water etc. are mentioned.
- higher fatty acid esters such as petrolatum, liquid paraffin, isopropyl myristate, octyldodecyl
- the composition of this invention can be made into the unit packaging form per ingestion amount.
- the “unit packaging form per intake” means a form in which one unit or two or more units are packaged with a single intake as one unit.
- a packaging material, a packaging method, and a filling method eg, packaging packaging, stick packaging, etc.
- the “single intake” is, for example, the amount of the composition to be administered at one time when the composition of the present invention is a medicine.
- the single intake can be appropriately adjusted according to the age, weight, gender, etc. of the person who takes the intake.
- the single dose of the composition of the present invention is not particularly limited as long as it is appropriately set according to the form of the composition, the dosage form, the subject of intake, etc., but in the case of a general adult (body weight 60 kg), 0.2 to 12.0 g is preferable, more preferably 0.3 to 10.0 g, and particularly preferably 0.5 to 8.0 g.
- the single intake of the composition of the present invention is within the above range, the normal diet is not significantly affected, and continuous intake can be expected.
- serine When the composition of the present invention is in a unit package form per ingestion, serine may be contained in an amount of 0.1 g or more (more preferably 0.2 g or more, particularly preferably 0.3 g or more). preferable.
- the serine content in this case is preferably 10.0 g or less (more preferably 8.0 g or less, particularly preferably 5.0 g or less) in one unit.
- the content is less than 0.1 g in one unit, serine is used as a constituent component or energy source of protein in the body, and thus a desired effect tends not to be expected.
- the said content exceeds 10.0g in 1 unit, a single amino acid will be ingested in large quantities, and it is not so preferable from a viewpoint of an amino acid balance.
- the content of threonine is 0.15 g or less (more preferably 0.1 g or less, more preferably 0.05 g or less, particularly preferably 1 unit). Preferably it is 0.025 g or less.
- n-3 fatty acid content is preferably 6.00 g or less (more preferably 4.50 g or less, particularly preferably 3.00 g or less) in one unit.
- the content is less than 0.03 g per unit, the desired effect tends not to be clearly expected.
- the said content exceeds 6.00g in 1 unit, it is not much preferable from a viewpoint of flavor.
- eicosapentaenoic acid when the n-3 fatty acid contains eicosapentaenoic acid and is in a unit packaging form per ingestion, eicosapentaenoic acid is contained in one unit, preferably 20 to 4000 mg, More preferably 30 to 3000 mg, particularly preferably 40 to 2000 mg.
- the daily intake of serine can be appropriately set according to the age, sex, weight, dietary conditions, etc. of the person who takes it, but is usually 0.1-10.0 g for a normal adult (body weight 60 kg) It is preferably 0.2 to 8.0 g, more preferably 0.3 to 5.0 g.
- eicosapentaenoic acid is recommended to be taken in an amount of 1 g or more per day together with docosahexaenoic acid in the case of general adults (weight 60 kg) based on the past lipid intake situation.
- composition of the present invention is once to several times a day (preferably 1 to 1 day a day) so that the daily intake amounts of serine, n-3 fatty acid and eicosapentaenoic acid are within the above ranges, respectively. (3 times) preferably taken.
- the composition of the present invention When the composition of the present invention is applied to animals other than humans, the above-mentioned one-time intake, the content in one unit, the daily intake, etc. What is necessary is just to adjust suitably according to a body weight or a magnitude
- the dose of each component (serine and the like) of the composition of the present invention may be determined based on the experimental results of animals other than humans. For example, when estimating the dose to humans from the results of experiments using rats, it can be assumed that the intake per body weight of rats and the intake per human body weight are equal.
- composition of the present invention can be produced by a method known per se in the field of pharmaceutical technology and the like (for example, the method described in the 16th revised Japanese Pharmacopeia).
- composition of the present invention is useful for prevention or improvement of peripheral neuropathy.
- it is useful for the relief of hypersensitive pain of peripheral neuropathy. It is also useful for preventing or improving a decrease in activity due to peripheral neuropathy.
- the composition of the present invention is useful for the prevention or improvement of peripheral neuropathy caused by an anticancer agent.
- Peripheral neuropathy caused by an anticancer drug occurs in the patient's body as the anticancer drug attacks the cancer. Due to the persistent pain throughout the body, anticancer drug treatment may have to be discontinued. Since the composition of the present invention can reduce the pain of peripheral neuropathy caused by an anticancer agent, it is useful for continuing treatment with an anticancer agent.
- the anticancer agent is not particularly limited as long as it can cause peripheral neuropathy.
- taxane anticancer agents such as paclitaxel and docetaxel
- platinum complex anticancer agents such as oxaliplatin, cisplatin and carboplatin Cancer agents
- Vinca alkaloid anticancer agents such as vincristine
- alkylating agent anticancer agents such as ifosfamide
- antimetabolite anticancer agents such as methotrexate, fluorouracil, cytarabine
- antibiotics such as doxorubicin and bleomycin Examples include anticancer agents.
- the composition of the present invention is useful for the prevention or improvement of peripheral neuropathy due to osteoarthritis of the knee.
- the composition of the present invention is useful for preventing or ameliorating disuse syndrome.
- Osteoarthritis of the knee occurs frequently in elderly women and is a representative example of locomotive syndrome. Since knee osteoarthritis is accompanied by intense pain as the stage progresses, it reduces the amount of activity of patients (eg, elderly people) and weakens the muscles of the legs. As a result, the burden on the knee is further increased, and the knee arthropathy is further aggravated, resulting in a negative spiral in which a disuse syndrome is developed. In addition, the decrease in the opportunity for elderly people to go out affects depression, dementia, continuation of independent life, and the like. Since the composition of the present invention can reduce pain in the knee joint, it is useful for escape from the negative spiral described above.
- Peripheral neuropathy pain is caused by abnormalities in sensory neurons that transmit sensory organ signals in the extremities.
- Cell bodies of sensory neurons exist in the dorsal root ganglia, and transmit stimulation signals by extending nerve fibers to the ends of the extremities and the inside of the spinal cord.
- abnormalities such as hyperdepolarization occur in areas where dorsal root ganglia and information inside the spinal cord are integrated, resulting in hypersensitive pain in various parts of the body. Arise.
- peripheral neuropathy examples include spinal nerve disorders (eg, herniated disc, lumbar spinal canal stenosis, degenerative spondylosis, etc.), mechanical compression of peripheral nerve trunk Peripheral neuropathy, diabetic peripheral neuropathy, renal disease urine toxicity peripheral neuropathy, peripheral neuropathy due to shingles, Guillain-Barre syndrome and the like.
- spinal nerve disorders eg, herniated disc, lumbar spinal canal stenosis, degenerative spondylosis, etc.
- the composition of the present invention is preferably used for the pain of these peripheral neuropathies.
- the limb with pain tends to decrease in momentum, while the other limb tends to increase because it tries to compensate for the decreased momentum. It is in.
- the muscle balance between the left and right limbs may be lost and physical ability may be reduced.
- Such a change in muscle balance and a decrease in physical ability can be caused not only by the pain of peripheral neuropathy due to the above knee osteoarthritis, but also by joint pain of the limbs due to sports, rheumatism, gout and the like.
- the composition of the present invention is preferably used for such a change in muscle balance and a decrease in physical ability.
- the present invention provides a method for preventing or ameliorating peripheral neuropathy, comprising administering an effective amount of the composition of the present invention to a subject in need thereof, and an effective amount of the composition of the present invention. Also provided is a method for preventing or ameliorating a decrease in activity due to peripheral neuropathy, which comprises administering to a subject in need thereof.
- medical practice refers to an act of treating, operating or diagnosing a human being performed by a doctor or dentist or under the supervision of a doctor or dentist.
- Example 1 Granular powder nutritional composition 1 Each component shown in Table 2 was mixed for 5 minutes in a small high speed mixer (NSK-150S, manufactured by Okada Seiko Co., Ltd.). Thereafter, 2 to 5% by weight of distilled water and 99.5% alcohol was added to the mixture, and the mixture was further kneaded for 5 minutes to obtain a wet kneaded product. Next, the wet kneaded product was granulated using an extrusion granulator equipped with a 1.0 mm ⁇ screen, and the resulting molded product was dried at normal pressure 70 ° C. for 2 hours and then sized to 1.05 g. The granules were filled into aluminum bags.
- the granular powder nutritional composition 1 thus obtained, all components were stably present even after being stored for 1 year under the condition of 24 ° C. Moreover, even if this granular powder nutrition composition 1 melt
- Example 2 Granular powder nutritional composition 2
- granulation was carried out in the same manner as in Example 1 except that kneading was performed using a mortar instead of a high speed mixer, and a horizontal extruder (manufactured by Umeda Iron Works Co., Ltd.) was used as the extrusion granulator.
- a powdery powder nutritional composition 2 was obtained.
- Example 3 Liquid composition capsule-filled product Each component shown in Table 3 was mixed, filled in a vegetable capsule soft capsule so that the total weight was 343.747 mg, and packed in an aluminum bag. In the liquid compositions thus obtained (Examples 2-1 and 2-2), all components were stably present even after storage for 1 year under conditions of 24 ° C. and humidity of 78%.
- the Von Frey test is the presence or absence of a reaction (pain response) that pulls in the foot when filaments of different thickness (stimulus intensity: 4g, 8g, 15g) are pressed against the center of the sole at a right angle at right angles. By observing. Each filament was pressed 5 times against the left and right feet. The pressing interval was 5 minutes. For each stimulation intensity, the ratio (%) of the frequency of pain response to the number of times the filament was pressed (5 times) was calculated.
- FIG. 3 shows the test results for the right foot 7 days after administration of the knee arthritis inducer
- FIG. 4 shows the test results for the left foot.
- FIG. 5 shows the test results for the right foot 14 days after administration of the knee arthritis inducer
- FIG. 6 shows the test results for the left foot.
- FIG. 7 shows the measurement results of the weight of the right foot and left foot.
- FIG. 8 shows the ratio (right foot / left foot) between the weight of the right foot and the left foot.
- the number of pain responses in the group 2B after 7 days and 14 days from the start of administration of the evaluation solution (that is, 7 days and 14 days after administration of the knee arthritis inducer)
- the left foot significantly increased compared to the 2A group.
- the number of pain responses was slightly reduced at any stimulation intensity compared to the group 2B, and the effect of alleviating hypersensitive pain was observed. The degree was not significant.
- the group (2D group) to which eicosapentaenoic acid was administered alone there was almost no change in the number of pain responses compared to the 2B group at any stimulation intensity.
- the weight of the right foot of the group that received the knee arthritis inducer was higher than that of the group that did not receive the knee arthritis inducer (group 2A). A downward trend was observed. Comparing the weight of the right foot of the 2C group to the 2E group, the 2E group was the highest, followed by the 2D group, and the 2C group was the lowest.
- the group to which the knee arthritis inducer was administered shook the right foot
- the weight of the left foot of the group showed an increasing tendency compared to the group to which the knee arthritis inducer was not administered. The difference between the weight of the right foot and the left foot was highest in the 2B group, and a difference of 10% or more was recognized.
- Group 3A distilled water
- Group 3B distilled water
- 3F group L-serine 10.5 mg / kg
- the Von Frey test is the presence or absence of a reaction (pain response) that pulls in the foot when filaments of different thickness (stimulus intensity: 4g, 8g, 15g) are pressed against the center of the sole at a right angle at right angles. By observing. Each filament was pressed 5 times against the right foot. The pressing interval was 5 minutes. For each stimulation intensity, the ratio (%) of the frequency of pain response to the number of times the filament was pressed (5 times) was calculated. The test results for the right foot 21 days after administration of the knee arthritis inducer are shown in FIG.
- the number of pain responses in the 3B group administered with the knee arthritis inducing agent was significantly increased as compared to the 3A group.
- the 3C to 3F groups in which the dose of L-threonine was changed did not show a significant decrease in the number of pain responses at any stimulation intensity compared to the 3B group.
- significant reductions were observed in many stimulation intensities. That is, when the weight ratio of L-serine to L-threonine (L-serine / L-threonine) is 2.56 or less, the effect of reducing hypersensitivity pain is not observed, while the ratio of L-serine is further increased. The above alleviating effect was observed at a high 5.25 or more.
- the weight ratio of serine to threonine is 2.56 in order to sufficiently exert the effect of reducing hypersensitive pain. It became clear that it was preferable to exceed.
- the amount of L-serine ingested in groups 4C to 4E is 10 mg / kg body weight, and EPA (eicosapentaenoic acid) has a fish oil equivalent to 100 mg / kg body weight (143 mg / body weight as n-3 fatty acids). kg equivalent amount) was used.
- Each group of meals is carried out at the same time as the start of the dark period, and the amount of threonine ingested by one meal is 313 mg / kg body weight in terms of free form.
- the amount of serine ingested by one meal is 489 mg / kg body weight in terms of free form, and the weight ratio of serine to threonine (serine / threonine) in the meal is 1.56.
- the number of pain responses in the 4B group administered with the knee arthritis inducing agent was significantly increased as compared to the 4A group.
- the 4C group to which L-serine and EPA were administered at a time point 9 hours after the start of the light period, which is a time zone 3 hours or more away from the immediately preceding meal a significant decrease in the number of pain responses or A downward trend was observed.
- the 4D group administered immediately before the meal no significant decrease was observed compared to the 4B group, and the number of pain responses increased compared to the 4C group.
- the 4E group administered 1 hour after the meal showed a significant decrease or tendency to decrease the number of pain responses compared to the 4B group, but when compared with the 4C group, the stimulation intensity was 8 g. And 15 g, the number of pain responses increased.
- the administration of the composition of the present invention is separated from the meal by at least 1 hour or more in order to sufficiently exert the alleviation of hypersensitivity pain by the composition of the present invention. It was inferred that the longer the distance, the better.
- composition of the present invention alleviates the pain of hypersensitivity and recovers the decreased amount of behavior.
- a composition for preventing or improving peripheral neuropathy can be provided.
- the composition has an effect of reducing pain of peripheral neuropathy, peripheral neuropathy caused by administration of an anticancer agent, peripheral neuropathy caused by osteoarthritis of the knee, spinal neuropathy (eg, disc herniation, lumbar region) Spinal canal stenosis, deformed spondylosis, etc., peripheral neuropathy due to mechanical compression of peripheral nerve trunk, diabetic peripheral neuropathy, renal urine peripheral neuropathy, peripheral neuropathy due to shingles, Guillain-Barre syndrome, etc.
- the said composition can prevent or improve the active mass fall by peripheral neuropathy.
- the composition contains L-serine and n-3 fatty acid, which have been established as safe, as active ingredients, it can be safely ingested over a long period of time, and the QOL of the ingestor can be increased.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Marine Sciences & Fisheries (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
[2]n-3系脂肪酸が、エイコサペンタエン酸、ドコサペンタエン酸及びドコサヘキサエン酸からなる群より選ばれる1種以上を含む、[1]記載の組成物。
[3]セリンの量が、アミノ酸の総量に対して50重量%以上である、[1]又は[2]記載の組成物。
[4](1)スレオニンを実質的に含まない、又は(2)スレオニンに対するセリンの重量比が、2.60以上である、[1]~[3]のいずれかに記載の組成物。
[5]n-3系脂肪酸の量が、脂質の総量に対して20重量%以上である、[1]~[4]のいずれかに記載の組成物。
[6]1回摂取量当たりの単位包装形態であり、且つ、セリンを1単位中0.1g以上含有し、n-3系脂肪酸を1単位中0.03g以上含有する、[1]~[5]のいずれかに記載の組成物。
[7]末梢神経障害が、抗がん剤による末梢神経障害、変形性膝関節症による末梢神経障害、背骨部神経障害、末梢神経幹の機械的圧迫による末梢神経障害、糖尿病性末梢神経障害、腎疾患尿毒性末梢神経障害、帯状疱疹による末梢神経障害及びギラン・バレー症候群からなる群より選ばれるいずれか1種である、[1]~[6]のいずれかに記載の組成物。
[8]末梢神経障害が、抗がん剤による末梢神経障害又は変形性膝関節症による末梢神経障害である、[1]~[6]のいずれかに記載の組成物。
[9]セリンを含むアミノ酸及びn-3系脂肪酸を含む脂質を含有する、末梢神経障害による活動量低下の予防又は改善用組成物。
[10]医薬である、[1]~[9]のいずれかに記載の組成物。
[12]n-3系脂肪酸が、エイコサペンタエン酸、ドコサペンタエン酸及びドコサヘキサエン酸からなる群より選ばれる1種以上を含む、[11]記載の方法。
[13]組成物中のセリンの量が、組成物中のアミノ酸の総量に対して50重量%以上である、[11]又は[12]記載の方法。
[14](1)組成物がスレオニンを実質的に含まない、又は(2)組成物中のスレオニンに対するセリンの重量比が、2.60以上である、[11]~[13]のいずれかに記載の方法。
[15]組成物中のn-3系脂肪酸の量が、組成物中の脂質の総量に対して20重量%以上である、[11]~[14]のいずれかに記載の方法。
[16]組成物が1回摂取量当たりの単位包装形態であり、且つ、セリンを1単位中0.1g以上含有し、n-3系脂肪酸を1単位中0.03g以上含有する、[11]~[15]のいずれかに記載の方法。
[17]末梢神経障害が、抗がん剤による末梢神経障害、変形性膝関節症による末梢神経障害、背骨部神経障害、末梢神経幹の機械的圧迫による末梢神経障害、糖尿病性末梢神経障害、腎疾患尿毒性末梢神経障害、帯状疱疹による末梢神経障害及びギラン・バレー症候群からなる群より選ばれるいずれか1種である、[11]~[16]のいずれかに記載の方法。
[18]末梢神経障害が、抗がん剤による末梢神経障害又は変形性膝関節症による末梢神経障害である、[11]~[16]のいずれかに記載の方法。
[19]セリンを含むアミノ酸及びn-3系脂肪酸を含む脂質を含有する組成物の有効量を、それを必要とする対象に投与することを含む、末梢神経障害による活動量低下の予防又は改善方法。
[21]n-3系脂肪酸が、エイコサペンタエン酸、ドコサペンタエン酸及びドコサヘキサエン酸からなる群より選ばれる1種以上を含む、[20]記載の組成物。
[22]セリンの量が、アミノ酸の総量に対して50重量%以上である、[20]又は[21]記載の組成物。
[23](1)スレオニンを実質的に含まない、又は(2)スレオニンに対するセリンの重量比が、2.60以上である、[20]~[22]のいずれかに記載の組成物。
[24]n-3系脂肪酸の量が、脂質の総量に対して20重量%以上である、[20]~[23]のいずれかに記載の組成物。
[25]1回摂取量当たりの単位包装形態であり、且つ、セリンを1単位中0.1g以上含有し、n-3系脂肪酸を1単位中0.03g以上含有する、[20]~[24]のいずれかに記載の組成物。
[26]末梢神経障害が、抗がん剤による末梢神経障害、変形性膝関節症による末梢神経障害、背骨部神経障害、末梢神経幹の機械的圧迫による末梢神経障害、糖尿病性末梢神経障害、腎疾患尿毒性末梢神経障害、帯状疱疹による末梢神経障害及びギラン・バレー症候群からなる群より選ばれるいずれか1種である、[20]~[25]のいずれかに記載の組成物。
[27]末梢神経障害が、抗がん剤による末梢神経障害又は変形性膝関節症による末梢神経障害である、[20]~[25]のいずれかに記載の組成物。
[28]末梢神経障害による活動量低下の予防又は改善における使用のための、セリンを含むアミノ酸及びn-3系脂肪酸を含む脂質を含有する組成物。
[29]医薬である、[20]~[28]のいずれかに記載の組成物。
本明細書において、末梢神経障害の「予防」とは、末梢神経障害の諸症状(例、過敏性の痛み、感覚異常等)を示していない個体において、該症状の顕在化を防ぐこと(再発防止も含む)を意味する。また、末梢神経障害の「改善」とは、末梢神経障害の諸症状を示している個体において、該症状を軽減すること、或いは該症状の悪化を防ぐこと又は遅延させることを意味する。
本発明において用いられるアミノ酸はセリンを必須として含む。当該セリンの形態は特に制限されず、遊離体、ペプチドの構成アミノ酸及びタンパク質の構成アミノ酸のいずれの形態であってよい。遊離のセリンを用いる場合、塩及びこれらの溶媒和物のいずれの形態であってもよく、また、これらの混合物であってもよい。
セリンの生理学的に許容し得る塩を形成する酸としては、例えば、塩化水素、臭化水素、硫酸、リン酸等の無機酸;酢酸、乳酸、クエン酸、酒石酸、マレイン酸、フマル酸、モノメチル硫酸等の有機酸が挙げられる。
セリンの生理学的に許容し得る塩を形成する塩基としては、例えば、金属(例、ナトリウム、カリウム、カルシウム等)の水酸化物又は炭酸化物、アンモニア等の無機塩基;エチレンジアミン、プロピレンジアミン、エタノールアミン、モノアルキルエタノールアミン、ジアルキルエタノールアミン、ジエタノールアミン、トリエタノールアミン等の有機塩基が挙げられる。
これらの塩は、1種単独の塩又は2種以上の塩の組み合わせのいずれでもよい。
本発明の組成物におけるセリンの量の上限は特に制限されないが、アミノ酸の総量に対して、通常100重量%であり、好ましくは95重量%である。
具体的には、スレオニンに対するセリンの重量比(セリン/スレオニン)は、好ましくは2.60以上であり、より好ましくは5.20以上であり、特に好ましくは10.40以上である。
ここで、スレオニンに対するセリンの重量比(セリン/スレオニン)とは、本発明の組成物におけるセリンの量を、本発明におけるスレオニンの量で除した値である。本発明の組成物におけるスレオニンの量は、本発明の組成物に含まれる全ての形態のスレオニンの重量の総和として算出される。スレオニンの形態が、遊離体以外、例えば塩、あるいはペプチド及びタンパク質の構成アミノ酸等である場合、当該スレオニンの重量は、遊離体の重量に換算する。
本発明の組成物において用いられる脂質は、n-3系脂肪酸を必須として含む。本明細書における「n-3系脂肪酸」とは、炭化水素鎖の末端のメチル基から3番目に二重結合を有する不飽和脂肪酸を意味し、具体的には、エイコサペンタエン酸、ドコサヘキサエン酸、α-リノレン酸及びドコサペンタエン酸等が例示される。本発明の組成物において用いられるn-3系脂肪酸は、エイコサペンタエン酸、ドコサヘキサエン酸及びドコサペンタエン酸が好ましく、エイコサペンタエン酸が特に好ましい。これらのn-3系脂肪酸は、単独で用いてもよいし、2種以上を併用してもよい。
本明細書中、エイコサペンタエン酸は「EPA」と略記される場合がある。
n-3系脂肪酸の量の上限は特に制限されない。
セリン及びn-3系脂肪酸を複数の組成物中に含有させる場合、アミノ酸の総量に対するセリンの量、脂質の総量に対するn-3系脂肪酸の量、n-3系脂肪酸の総量に対するエイコサペンタエン酸の含有量等は、複数の組成物に含まれる各成分の合計量から算出される。
本明細書において「1回摂取量」とは、例えば、本発明の組成物が医薬である場合は、1回に投与される組成物の量である。当該1回摂取量は、摂取する者の年齢、体重、性別等に応じて適宜調節できる。
また、n-3系脂肪酸は、日本では、過去の脂質摂取状況に基づき、一般の成人(体重60kg)の場合、1日当たり2g以上摂取することが推奨されている。
エイコサペンタエン酸は、日本では、過去の脂質摂取状況に基づき、一般の成人(体重60kg)の場合、ドコサヘキサエン酸と併せて、1日当たり1g以上摂取することが推奨されている。
本発明の組成物は、セリン、n-3系脂肪酸及びエイコサペンタエン酸の1日当たりの摂取量が、それぞれ上記の範囲内となるように、1日1回~数回(好ましくは1日1~3回)摂取されることが好ましい。
また、本発明の組成物をヒトに適用する場合、本発明の組成物の各成分(セリン等)の用量は、ヒト以外の動物の実験結果に基づいて決定してよい。例えば、ラットを用いた実験の結果からヒトへの用量を推定する場合は、ラットの体重当たりの摂取量とヒトの体重当たりの摂取量とは等しいと仮定できる。従って、例えば後述の実施例において、ラットにL-セリンを10.5mg/体重kgの量で摂取させることが記載されているが、該記載に基づき一般の成人(体重60kg)のL-セリンの摂取量を算出する場合、630mgとなる。同様に、ラットにL-スレオニンを2.0mg/体重kgの量で摂取させるという記載に基づき、一般の成人(体重60kg)のL-スレオニンの摂取量を算出する場合、120mgとなる。
これらの方法は、医療行為を除くものであってよい。ここで「医療行為」とは、医師又は歯科医師によって、あるいは、医師又は歯科医師の指導監督の下で行われる、ヒトを治療、手術又は診断する行為をいう。
表2に示す各成分を、小型のハイスピードミキサー(NSK-150S、岡田精工株式会社製)中で5分間混合した。その後、該混合物に蒸留水および99.5%アルコールを2~5重量%加え、さらに該ミキサーで5分間混練を行い、湿潤混練物を得た。次に該湿潤混練物を1.0mmφのスクリーンの付いた押出し造粒機を用いて造粒し、得られた成形物を常圧70℃で2時間乾燥した後、整粒して1.05gの顆粒をアルミ製の袋に充填した。このようにして得られた顆粒状粉体栄養組成物1は、24℃の条件下で1年保管した後においても全成分は安定に存在した。また、この顆粒状粉体栄養組成物1は、温水に溶解し栄養剤に混合してしても、使用することができ、イオン飲料とすることもできた。更に香辛料、食塩などの塩類、グルタミン酸ナトリウム、核酸などと混ぜ合わせ、様々な食品に添加できた。
実施例1において、ハイスピードミキサーの代わりに乳鉢を用いて混練を行い、また押出し造粒機として横型押出し機(有限会社梅谷鉄工所製)を用いた以外は実施例1と同様にして、顆粒状粉体栄養組成物2を得た。
表3に示す各成分を混合し、総重量が343.747mgになるように、植物性被膜のソフトカプセルに充填し、アルミ製の袋に詰めた。このようにして得られた液状組成物(実施例2-1、2-2)は、24℃、湿度78%の条件下で1年保存した後においても、全ての成分が安定に存在した。
本発明の組成物の、抗がん剤による過敏性の痛みの軽減効果を、以下の実験により検討した。
6週齢の雄性SDラットを、体重を基に5群(1A群~1E群、N=6)に群分けし、1A群以外の4群には抗がん剤(Oxaliplatin 5mg/体重kg)を5日間腹腔内投与し、1A群には生理食塩水を5日間腹腔内投与した。また、腹腔内投与の開始と同時に28日間、下記の評価液を毎日1回、明期開始後4~5時間の時間帯に、経口摂取させた。1D群、1E群に投与したエイコサペンタエン酸には、300mg/体重kgに相当する魚油(n-3系脂肪酸として429mg/体重kg相当量)を用いた。
[1A群~1E群の評価液]
1A群:蒸留水
1B群:蒸留水
1C群:L-セリン 10.5mg/体重kg
1D群:エイコサペンタエン酸 300mg/体重kg相当量
1E群:L-セリン 10.5mg/体重kg+エイコサペンタエン酸 300mg/体重kg相当量
抗がん剤の投与開始から22日後及び28日後にVon Frey試験を実施した。Von Frey試験は、太さの異なるフィラメント(刺激強度:4g、8g、15g)を、それぞれ一定速度で足裏の中央部に直角に押し当てた際の、足を引き込む反応(痛み応答)の有無を観察することによって行った。各フィラメントは、左右の足に対しそれぞれ5回ずつ、計10回押し当てた。押し当てる間隔は、5分間とした。各刺激強度において、フィラメントを押し当てた回数(10回)に対する痛み応答の回数の割合(%)を算出した。
抗がん剤の投与開始から22日後の試験結果を図1に、抗がん剤の投与開始から28日後の試験結果を図2に示す。
セリンを単独投与した群(1C群)では、いずれの刺激強度においても、1B群に比べて、痛み応答の回数が僅かに減少し、過敏性の痛みの軽減効果が認められたが、その程度は有意ではなかった。
エイコサペンタエン酸を単独投与した群(1D群)では、いずれの刺激強度においても、1B群と比べて、痛み応答の回数に変化は殆ど見られなかった。
セリンとエイコサペンタエン酸とを併用投与した群(1E群)では、1B群に比べて、痛み応答の回数が顕著に減少し、有意な過敏性の痛みの軽減効果が認められた。
本発明の組成物の、膝関節炎における過敏性の痛みの軽減効果を、以下の実験により検討した。
8週齢の雄性SDラットを、体重を基に5群(2A群~2E群、N=7)に群分けし、2A群以外の4群には膝関節炎誘発剤(Zymosan)を右膝軟骨部に2mg投与した。また、右膝への膝関節炎誘発剤の投与から21日間、下記の評価液を毎日1回、明期開始後4~5時間の時間帯に、経口摂取させた。2D群、2E群に投与したエイコサペンタエン酸には、300mg/体重kgに相当する魚油(n-3系脂肪酸として429mg/体重kg相当量)を用いた。
[2A群~2E群の評価液]
2A群:蒸留水
2B群:蒸留水
2C群:L-セリン 10.5mg/体重kg
2D群:エイコサペンタエン酸 300mg/体重kg相当量
2E群:L-セリン 10.5mg/体重kg+エイコサペンタエン酸 300mg/体重kg相当量
膝関節炎誘発剤の投与から7日後及び14日後に、Von Frey試験を実施した。Von Frey試験は、太さの異なるフィラメント(刺激強度:4g、8g、15g)を、それぞれ一定速度で足裏の中央部に直角に押し当てた際の、足を引き込む反応(痛み応答)の有無を観察することによって行った。各フィラメントは、左右の足に対しそれぞれ5回ずつ押し当てた。押し当てる間隔は、5分間とした。各刺激強度において、フィラメントを押し当てた回数(5回)に対する痛み応答の回数の割合(%)を算出した。
膝関節炎誘発剤の投与から7日後の右足に対する試験結果を図3に、左足に対する試験結果を図4に示す。また、膝関節炎誘発剤の投与から14日後の右足に対する試験結果を図5に、左足に対する試験結果を図6に示す。
L-セリンを単独投与した群(2C群)では、いずれの刺激強度においても、2B群に比べて、痛み応答の回数が僅かに減少し、過敏性の痛みの軽減効果が認められたが、その程度は有意ではなかった。
エイコサペンタエン酸を単独投与した群(2D群)では、いずれの刺激強度においても、2B群と比べて、痛み応答の回数に変化は殆ど見られなかった。
L-セリンとエイコサペンタエン酸とを併用投与した群(2E群)では、2B群に比べて、痛み応答の回数が顕著に減少した。特に、膝関節炎誘発剤の投与から14日後は、刺激強度8g及び15gにおいて、両足ともに、痛み応答の回数の有意な減少又は減少傾向が認められた。
本発明の組成物による過敏性の痛みの軽減効果への、スレオニン添加の影響を、以下の実験により検討した。
8週齢の雄性SDラットを、体重を基に6群(3A群~3F群、N=6)に群分けし、3A群以外の5群には膝関節炎誘発剤(Zymosan)を右膝軟骨部に2mg投与した。また、右膝への膝関節炎誘発剤の投与の翌日から、下記の評価液を毎日1回、明期開始後4~5時間の時間帯に、経口摂取させた。3C群~3F群に投与したエイコサペンタエン酸には、100mg/体重kgに相当する魚油(n-3系脂肪酸として143mg/体重kg相当量)を用いた。また以下の通り、3C群~3F群は、L-セリンの投与量を10mg/体重kgに固定し、L-スレオニンの投与量を0.8~8.1mg/体重kgに変化させた。
[3A群~3F群の評価液]
3A群:蒸留水
3B群:蒸留水
3C群:L-セリン 10.5mg/体重kg+エイコサペンタエン酸 100mg/体重kg相当量+L-スレオニン 8.1mg/体重kg(L-セリン/L-スレオニン=1.30)
3D群:L-セリン 10.5mg/体重kg+エイコサペンタエン酸 100mg/体重kg相当量+L-スレオニン 4.1mg/体重kg(L-セリン/L-スレオニン=2.56)
3E群:L-セリン 10.5mg/体重kg+エイコサペンタエン酸 100mg/体重kg相当量+L-スレオニン 2.0mg/体重kg(L-セリン/L-スレオニン=5.25)
3F群:L-セリン 10.5mg/体重kg+エイコサペンタエン酸 100mg/体重kg相当量+L-スレオニン 0.8mg/体重kg(L-セリン/L-スレオニン=13.13)
膝関節炎誘発剤の投与から21日後に、Von Frey試験を実施した。Von Frey試験は、太さの異なるフィラメント(刺激強度:4g、8g、15g)を、それぞれ一定速度で足裏の中央部に直角に押し当てた際の、足を引き込む反応(痛み応答)の有無を観察することによって行った。各フィラメントは、右足に対しそれぞれ5回ずつ押し当てた。押し当てる間隔は、5分間とした。各刺激強度において、フィラメントを押し当てた回数(5回)に対する痛み応答の回数の割合(%)を算出した。
膝関節炎誘発剤の投与から21日後の右足に対する試験結果を図9に示す。
L-スレオニンの投与量を変化させた3C~3F群のうち、3C群及び3D群では、3B群に比べて、いずれの刺激強度においても、痛み応答回数の有意な低下は認められなかったが、3E群及び3F群では、多くの刺激強度において有意な低下が認められた。即ち、L-スレオニンに対するL-セリンの重量比(L-セリン/L-スレオニン)が、2.56以下では、過敏性の痛みの軽減効果が認められず、一方、よりL-セリンの比率の高い5.25以上では当該軽減効果が認められた。
本発明の組成物による過敏性の痛みの軽減効果への、食事の影響を、以下の実験により検討した。
8週齢の雄性SDラットを、体重を基に5群(4A群~4E群、N=6)に群分けし、4A群以外の4群には膝関節炎誘発剤(Zymosan)を右膝軟骨部に2mg投与した。また、右膝への膝関節炎誘発剤の投与の翌日から、下記の評価液を毎日1回、下記の投与時間帯に、経口摂取させた。4C群~4E群に摂取させたL-セリンの量は10mg/体重kgであり、またEPA(エイコサペンタエン酸)には、100mg/体重kgに相当する魚油(n-3系脂肪酸として143mg/体重kg相当量)を用いた。各群の食事は毎日、暗期開始と同時に行われ、また1回の食事により摂取されるスレオニンの量は、遊離体換算で、313mg/体重kgである。また、1回の食事により摂取されるセリンの量は、遊離体換算値で489mg/体重kgであり、当該食事のスレオニンに対するセリンの重量比(セリン/スレオニン)は1.56となる。
[4A群~4F群の評価液および投与時間帯]
4A群:蒸留水/明期開始から9時間後の時点で投与
4B群:蒸留水/明期開始から9時間後の時点で投与
4C群:L-セリン+EPA/明期開始から9時間後の時点で投与
4D群:L-セリン+EPA/食事の直前に投与
4E群:L-セリン+EPA/食事から1時間後の時点で投与
膝関節炎誘発剤の投与から14日後に、Von Frey試験を実施した。Von Frey試験は、試験例3と同様の手順で行った。
膝関節炎誘発剤の投与から14日後の右足に対する試験結果を図10に示す。
直前の食事から3時間以上離れた時間帯である明期開始から9時間後の時点に、L-セリン及びEPAを投与した4C群では、4B群に比べて、痛み応答回数の有意な低下又は低下傾向が認められた。一方、食事の直前に投与した4D群では、4B群に比べ有意な低下が認められず、4C群に比べて痛み応答回数が増加した。更に、食事から1時間後の時点で投与した4E群は、4B群に比べて、痛み応答回数の有意な低下又は低下傾向が認められたものの、4C群と比べた場合には、刺激強度8gと15gにおいて、痛み応答回数が増加した。
本発明の組成物の行動量に対する影響を、以下の実験により検討した。
8週齢の雄性SDラットを、体重を基に3群(5A群~5C群、N=6)に群分けし、5A群以外の2群には膝関節炎誘発剤(Zymosan)を右膝軟骨部に2mg投与した。また、右膝への膝関節炎誘発剤の投与の翌日から、下記の評価液を毎日1回、明期開始後4~5時間の時間帯に、経口摂取させた。5C群に投与したエイコサペンタエン酸には、100mg/体重kgに相当する魚油(n-3系脂肪酸として143mg/体重kg相当量)を用いた。
[5A群~5C群の評価液]
5A群:蒸留水
5B群:蒸留水
5C群:L-セリン 10.5mg/体重kg+エイコサペンタエン酸 100mg/体重kg相当量
膝関節炎誘発剤の投与から7日後及び14日後に、赤外線センサーを用いた行動量測定装置(SUPERMEX、室町機械株式会社製)によって、終日行動量を測定した。当該7日後及び14日後の暗期(12時間)における行動量の測定結果を図11に示す。
Claims (12)
- セリンを含むアミノ酸及びn-3系脂肪酸を含む脂質を含有する、末梢神経障害の予防又は改善用組成物。
- n-3系脂肪酸が、エイコサペンタエン酸、ドコサペンタエン酸及びドコサヘキサエン酸からなる群より選ばれる1種以上を含む、請求項1記載の組成物。
- セリンの量が、アミノ酸の総量に対して50重量%以上である、請求項1又は2記載の組成物。
- (1)スレオニンを実質的に含まない、又は(2)スレオニンに対するセリンの重量比が、2.60以上である、請求項1~3のいずれか1項に記載の組成物。
- n-3系脂肪酸の量が、脂質の総量に対して20重量%以上である、請求項1~4のいずれか1項に記載の組成物。
- 1回摂取量当たりの単位包装形態であり、且つ、セリンを1単位中0.1g以上含有し、n-3系脂肪酸を1単位中0.03g以上含有する、請求項1~5のいずれか1項に記載の組成物。
- 末梢神経障害が、抗がん剤による末梢神経障害、変形性膝関節症による末梢神経障害、背骨部神経障害、末梢神経幹の機械的圧迫による末梢神経障害、糖尿病性末梢神経障害、腎疾患尿毒性末梢神経障害、帯状疱疹による末梢神経障害及びギラン・バレー症候群からなる群より選ばれるいずれか1種である、請求項1~6のいずれか1項に記載の組成物。
- 末梢神経障害が、抗がん剤による末梢神経障害又は変形性膝関節症による末梢神経障害である、請求項1~6のいずれか1項に記載の組成物。
- セリンを含むアミノ酸及びn-3系脂肪酸を含む脂質を含有する、末梢神経障害による活動量低下の予防又は改善用組成物。
- 医薬である、請求項1~9のいずれか1項に記載の組成物。
- セリンを含むアミノ酸及びn-3系脂肪酸を含む脂質を含有する組成物の有効量を、それを必要とする対象に投与することを含む、末梢神経障害の予防又は改善方法。
- 末梢神経障害の予防又は改善における使用のための、セリンを含むアミノ酸及びn-3系脂肪酸を含む脂質を含有する組成物。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15783692.5A EP3135281B8 (en) | 2014-04-22 | 2015-04-21 | Composition for preventing or improving peripheral neuropathy |
JP2016514944A JP6775419B2 (ja) | 2014-04-22 | 2015-04-21 | 末梢神経障害の予防又は改善用組成物 |
CN201580021078.4A CN106232114B (zh) | 2014-04-22 | 2015-04-21 | 周围神经病变的预防或改善用组合物 |
US15/298,953 US20170035721A1 (en) | 2014-04-22 | 2016-10-20 | Composition for preventing or improving peripheral neuropathy |
US16/129,875 US10653655B2 (en) | 2014-04-22 | 2018-09-13 | Composition for preventing or improving peripheral neuropathy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014088051 | 2014-04-22 | ||
JP2014-088051 | 2014-04-22 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/298,953 Continuation US20170035721A1 (en) | 2014-04-22 | 2016-10-20 | Composition for preventing or improving peripheral neuropathy |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015163316A1 true WO2015163316A1 (ja) | 2015-10-29 |
Family
ID=54332480
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/062092 WO2015163316A1 (ja) | 2014-04-22 | 2015-04-21 | 末梢神経障害の予防又は改善用組成物 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20170035721A1 (ja) |
EP (1) | EP3135281B8 (ja) |
JP (2) | JP6775419B2 (ja) |
CN (1) | CN106232114B (ja) |
WO (1) | WO2015163316A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018027925A (ja) * | 2016-08-19 | 2018-02-22 | 株式会社明治 | 抗がん剤に起因する末梢神経障害を改善するための組成物 |
WO2019146735A1 (ja) | 2018-01-26 | 2019-08-01 | 味の素株式会社 | 侵害受容性疼痛の予防又は改善用組成物 |
CN115397960A (zh) * | 2020-01-30 | 2022-11-25 | 硅循环股份有限公司 | 制备多不饱和脂肪酸的固体中性氨基酸盐的方法 |
WO2023002979A1 (ja) * | 2021-07-20 | 2023-01-26 | 学校法人近畿大学 | 新規化合物およびそれを用いた末梢神経障害の予防又は改善剤 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011111355A1 (ja) * | 2010-03-10 | 2011-09-15 | 北海道公立大学法人札幌医科大学 | L-セリンを含有する末梢神経障害の予防・治療剤 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1151800C (zh) * | 1999-07-23 | 2004-06-02 | 王钢柱 | 一种治疗糖尿病周围神经病变的药物 |
IT1316998B1 (it) * | 2000-03-02 | 2003-05-26 | Sigma Tau Healthscience Spa | Composizione per la prevenzione e/o il trattamento degli effetticitotossici indotti dall'uso di agenti immunosoppressori. |
DE10340740A1 (de) * | 2003-09-04 | 2005-03-31 | Degussa Food Ingredients Gmbh | Physiologisch aktive Zusammensetzung auf Phosphatidylserin-Basis |
-
2015
- 2015-04-21 WO PCT/JP2015/062092 patent/WO2015163316A1/ja active Application Filing
- 2015-04-21 EP EP15783692.5A patent/EP3135281B8/en active Active
- 2015-04-21 JP JP2016514944A patent/JP6775419B2/ja active Active
- 2015-04-21 CN CN201580021078.4A patent/CN106232114B/zh active Active
-
2016
- 2016-10-20 US US15/298,953 patent/US20170035721A1/en not_active Abandoned
-
2018
- 2018-09-13 US US16/129,875 patent/US10653655B2/en active Active
-
2019
- 2019-08-06 JP JP2019144227A patent/JP2019182881A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011111355A1 (ja) * | 2010-03-10 | 2011-09-15 | 北海道公立大学法人札幌医科大学 | L-セリンを含有する末梢神経障害の予防・治療剤 |
Non-Patent Citations (3)
Title |
---|
GHOREISHI ET AL.: "Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: A randomized double- blind placebo controlled trial", BMC CANCER, vol. 12, 2012, pages 355, XP021115528, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3459710/pdf/1471-2407-12-355.pdf> * |
KIYA ET AL.: "ROLE OF SATELLITE CELL -DERIVED L- SERINE IN THE DORSAL ROOT GANGLION IN PACRITAXEL-INDUCED PAINFUL PERIPHERAL NEUROPATHY", NEUROSCIENCE, vol. 174, 2011, pages 190 - 199, XP027589595 * |
SHAPIRO: "Could n-3 polyunsaturated fatty acids reduce pathological pain by direct actions on the nervous system?", PROSTAGLANDINS, LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, vol. 68, no. 3, 2003, pages 219 - 224, XP055233047 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018027925A (ja) * | 2016-08-19 | 2018-02-22 | 株式会社明治 | 抗がん剤に起因する末梢神経障害を改善するための組成物 |
WO2018034345A1 (ja) * | 2016-08-19 | 2018-02-22 | 株式会社明治 | 抗がん剤に起因する末梢神経障害を改善するための組成物 |
WO2019146735A1 (ja) | 2018-01-26 | 2019-08-01 | 味の素株式会社 | 侵害受容性疼痛の予防又は改善用組成物 |
US20200345677A1 (en) * | 2018-01-26 | 2020-11-05 | Ajinomoto Co., Inc. | Composition for preventing or improving nociceptive pain |
US11730713B2 (en) * | 2018-01-26 | 2023-08-22 | Ajinomoto Co., Inc. | Composition for preventing or improving nociceptive pain |
CN115397960A (zh) * | 2020-01-30 | 2022-11-25 | 硅循环股份有限公司 | 制备多不饱和脂肪酸的固体中性氨基酸盐的方法 |
WO2023002979A1 (ja) * | 2021-07-20 | 2023-01-26 | 学校法人近畿大学 | 新規化合物およびそれを用いた末梢神経障害の予防又は改善剤 |
Also Published As
Publication number | Publication date |
---|---|
EP3135281B8 (en) | 2020-12-23 |
US20170035721A1 (en) | 2017-02-09 |
EP3135281A1 (en) | 2017-03-01 |
JPWO2015163316A1 (ja) | 2017-04-20 |
CN106232114A (zh) | 2016-12-14 |
JP2019182881A (ja) | 2019-10-24 |
US10653655B2 (en) | 2020-05-19 |
EP3135281A4 (en) | 2017-12-20 |
CN106232114B (zh) | 2022-03-18 |
EP3135281B1 (en) | 2020-10-28 |
JP6775419B2 (ja) | 2020-10-28 |
US20190008814A1 (en) | 2019-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019182881A (ja) | 末梢神経障害の予防又は改善用組成物 | |
EP3340977B1 (en) | Compositions comprising urolithin compounds | |
US11878964B2 (en) | Compositions comprising an urolithin compound | |
JP2019031504A (ja) | トコトリエノールの経粘膜送達 | |
KR20100094485A (ko) | 아미노산 조성물을 함유하는 피로 방지제 | |
US20150050260A1 (en) | Pyrroloquinoline quinone based compositions and uses | |
EP3461479B1 (en) | Nutraceutical and pharmaceutical compositions, and uses thereof for preserving cognitive functions | |
WO2012036208A1 (ja) | 脂質燃焼又はエネルギー代謝促進剤 | |
US11730713B2 (en) | Composition for preventing or improving nociceptive pain | |
WO2007128465A1 (en) | Xanthone derivative for the treatment of muscular disorders | |
JPS6210018A (ja) | 肥満抑制組成物 | |
AU2022419516A1 (en) | Placental composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15783692 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016514944 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015783692 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015783692 Country of ref document: EP |